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NDRG (N-Myc downstream-regulated gene)-2 is a member of the
NDRG family. Although it has been suggested that NDRG2 is
involved in cellular differentiation and tumor suppression, its in-
tracellular signal and regulatory mechanism are not well known.
Here, we show the differential expression of NDRG2 in human
colon carcinoma cell lines and tissues by reverse transcription–
polymerase chain reaction and immunohistochemical analyses
with monoclonal antibody against NDRG2. NDRG2 was strongly
expressed in normal colonic mucosa and colonic adenomatous
tissues (25 of 25) but not in all invasive cancer tissues [44 of 99
(44%)]. Most distinctive results indicated that the high expression
level of NDRG2 has a positive correlation with tumor differenti-
ation and inverse correlation with tumor invasion depth and
Dukes’ stage of colon adenocarcinoma. To investigate the roles
of NDRG2 in tumorigenesis, we used in vitro cell culture system.
SW620 colon cancer cell line with a low level of intrinsic NDRG2
protein was transfected with NDRG2-expressing plasmid.
TOPﬂash luciferase reporter assay showed that the transcrip-
tional activity of T-cell factor (TCF)/lymphoid enhancer factor
(LEF) was reduced by NDRG2 introduction, but not by the
introduction of mutant NDRG2 generated by deletion or site-
directed mutagenesis. Intracellular b-catenin levels were slightly
reduced in the NDRG2-transfected SW620 cells and this regula-
tion of b-catenin stability and TCF/LEF activity were mediated
through the modulation of glycogen synthase kinase-3beta activ-
ity by NDRG2 function. Our results suggest that NDRG2 might
play a pivotal role as a potent tumor suppressor by the attenua-
tion of TCF/b-catenin signaling for the maintenance of healthy
colon tissues.
Introduction
N-Myc downstream-regulated gene (NDRG)-2, which belongs to the
NDRG family, comprised of four identiﬁed members; NDRG1–4
have been implicated in the regulation of cell differentiation and
proliferation. NDRG1 is the most widely observed member of
the NDRG family in various tissues of different species, whereas
NDRG2–4 have been reported to be restricted to specialized organs
or tissues including brain and heart, suggesting their different but
related speciﬁc functions in different tissues and organs (1–3). In
addition to NDRG2 expression in normal human tissues, differential
expression of NDRG2 was reported in some human tumor tissues or
cell lines including meningioma (4), liver and pancreatic cancer (5)
and glioblastoma (6). In these studies, the expression of NDRG2 was
signiﬁcantly downregulated in a variety of different malignant neo-
plasms compared with the corresponding normal or benign tissues,
which suggested that it might have a role in the modulation of the
aggressive behavior of tumor progression. Indeed, accumulated evi-
dence suggests that NDRG2 plays a role as a tumor suppressor, butthe
exact intracellular functional role of the NDRG2 remains to be clar-
iﬁed further, although much effort has been devoted to the investiga-
tion of NDRG2 function in cultured cells and animal systems.
NDRG2 was identiﬁed as a novel target molecule of antidepres-
sants and electroconvulsive treatment in the central nervous system
(7). Furthermore, Nichols et al. (8) conﬁrmed that NDRG2 has a
putative role in neural differentiation, synapse formation and axon
survival in response to glucocorticoids. It was also reported that
NDRG2 was upregulated with disease pathogenesis in the human
brain disease, Alzheimer disease (9). Interestingly, Choi et al. (10)
reported that NDRG2 is involved in the process of dendritic cells
differentiation of monocytes, CD34 precursor and leukemia cells by
any maturation-inducing stimuli. NDRG2 might have speciﬁc func-
tions in the regulation of cellular differentiation and the maintenance
of the status of various tissues or organs.
The structure of NDRG2 is composed of an a/b-hydrolase domain
in the N-terminal region and several potential phosphorylation sites in
the C-terminal region that contains three consensus Akt phosphory-
lation sites. Burchﬁeld et al. (11) reported that NDRG2 is regulated by
insulin-dependent phosphorylation in C2C12 skeletal muscle cells. It
has been reported that NDRG2 is induced by mineralocorticoid
hormones such as aldosterone (12) and has been identiﬁed as a phys-
iological substrate phosphorylated by serum- and glucocorticoid-
induced kinase 1 in vitro (13). However, the precise physiological
role of NDRG2 phosphorylation is not yet known.
Human colorectal cancer is the leading cause of cancer death in the
USA when smoking-related cancers are excluded. Colorectal cancer
frequently involves genetic inactivation of the Wnt signal transduc-
tion system. Wnt ligands initiate a signaling cascade that reaches the
nucleus via rapid movement of cytoplasmic b-catenin through nuclear
pores. To effect this nuclear localization, the Wnt signal inhibits the
activity of serine/threonine kinase glycogen synthase kinase-3beta
(GSK-3b) (14–16). Under normal conditions, free b-catenin is rapidly
phosphorylatedby GSK-3b and subsequently degraded in the ubiquitin–
proteasome pathway. When the Wnt signal is activated or the tumor
suppressor adenomatous polyposis coli (APC) is non-functional, which
occurs in many cases of colorectal cancer, GSK-3b activity is blocked.
As a result, high levels of b-catenin accumulate in the cytoplasm and
subsequently translocate into the nucleus after forming a complex
with the T-cell factor (TCF) or lymphoid enhancer factor (LEF),
which leads to the activation of Wnt target genes including cyclin
D1 and c-Myc (17–21). Wnt/b-catenin signaling is one of the key
signaling pathways in tumorigenesis, cell growth, motility and
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catenin is critical in the regulation of TCF/LEF activities.
Although NDRG2 expression in brain, breast, liver and pancreatic
cancer have been reported, differential expression and intracellular
function of NDRG2 in human colon cancer have not yet been inves-
tigated. We ﬁrst investigated the localization and expression pattern of
NDRG2 in colon tissues by immunohistochemical analysis as well as
the expression level of NDRG2 in human colon cancer cell lines. We
also looked at the function of NDRG2 in tumorigenesis, especially the
engagement of NDRG2 in Wnt signal by examiningthe modulation of
b-catenin. In NDRG2-overexpressing cells, we found a decrease in
levels of intracellular b-catenin and a subsequent decrease in TCF/
LEF transcription activities.
Materials and methods
Patient samples and cell lines
Human colorectal carcinoma samples were obtained from patients who un-
derwent routine surgery for colorectal cancer at the Department of Surgery,
Eulji University Hospital, between January 2002 and December 2005. For the
immunohistochemical study, 25 colorectal adenomatous tissues, 99 colorectal
carcinoma tissues and paired normal mucosal tissues taken from a site distant
from the tumorous lesion were ﬁxed in 10% neutralized-buffered formalin
solution for 24 h. Some of the tissue specimens were immediately kept frozen
after resection and stored in liquid nitrogen until further use. Each patient’s
clinical status was classiﬁed according to the pathological grade of the tumor
size, lymph node and metastasis classiﬁcation system. All cell lines used in our
studies were purchased from American Type Culture Collection (Rockville,
MD); KM12c, Colo205, HCT116, HT29, SW480 and SW620 cells. The cells
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium (Gibco BRL, Grand
Island, NY) supplemented with 2 mM glutamine, 1% penicillin–streptomycin
and 10% fetal bovine serum (Hyclon, Logan, UT) and kept at 37C in a hu-
midiﬁed incubator that was maintained with 5% CO2. Plasmid-containing
wild-type or mutant NDRG2 coding region was transfected into the SW620
cell line using Lipofectamine plus reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. For selection of the positive clones, 100
lg/ml of G418 (Sigma, St Louis, MO) was applied 48 h after transfection.
Three weeks later, the colonized cells were selected and then cultured for
further selection. After single cellular selection, the established cell lines were
identiﬁed by western blotting with anti-human NDRG2 antibody and main-
tained with normal growth medium containing 100 lg/ml of G418.
Antibodies, western blotting and immunoprecipitation
Anti-b-catenin monoclonal antibody (mAb) was obtained from BD Biosciences
(San Jose, CA). Anti-a-tubulin mAb and horseradish peroxidase-conjugated
anti-mouse or anti-rabbit immunoglobulin G (IgG) were purchased from Sigma.
The anti-phospho-b-catenin, anti-phospho-Akt, anti-Akt, anti-GSK-3b and anti-
phospho-GSK-3b wereacquiredfromCellSignalingTechnology(Beverly,MA).
Anti-His mAb was purchased from SantaCruz Biotechnology (Pasadena, CA).
mAb to NDRG2 protein was generated from a hybridoma cell line established
in house by fusing the splenocytes of Balb/c mice immunized with the re-
combinant NDRG2 protein with the SP2/0-Ag14 murine myeloma cells as
described in USA patent 11/3938979. During western blot analysis, the cells
were washed with phosphate-buffered saline (PBS) and lysed with cell lysis
buffer [20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM ethylene glycol tetra-
acetic acid, 1 mM ethylenediaminetetraacetic acid, 1% NP-40, 2.5 mM sodium
pyrophosphate, 1 mM Na3VO4, 1 mM NaF and protease inhibitors cocktail
(Sigma)] on ice for 30 min. The lysates were then clariﬁed by centrifugation
and total protein content in the cell lysates was quantiﬁed by Bradford assay.
The lysates were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis on 10 or 12% polyacrylamide gels and transferred to polyvi-
nylidene diﬂuoride membranes, and the membranes were blocked with 5%
non-fat dry skim milk in Tris-buffered saline (20 mM Tris–HCl, pH 7.4,
150 mM NaCl) at room temperature. After incubation with the appropriate
primary antibodies for 2 h at room temperature, the membranes were incubated
with horseradish peroxidase-conjugated secondary antibodies for 1 h and vi-
sualized with an ECL detection system (Amersham Pharmacia Biotech,
Piscataway, NJ). To detect the interaction of b-catenin and NDRG2, the lysates
from NDRG2-overexpressing SW620 and Colo205 cells were immunopreci-
pitated with an anti-NDRG2 antibody. The immunocomplexes were captured
by the protein G agarose (BD Biosciences), the precipitates were resolved by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and NDRG2 and
b-catenin were analyzed by western blotting. The inhibition of NDRG2 ex-
pression in NDRG2-overexpressed SW620 cells was achieved using 1 lgo f
NDRG2-speciﬁc SMARTPool small interfering RNA (siRNA) (Dharmacon,
Lafayette, CO). Cells were transfected by electroporation and immediately
Fig. 1. Differential expression of NDRG2 in colon tumor tissues and colon cancer cell lines. (A) NDRG2 mRNA levels in colon tumor tissues were evaluated by
RT–PCR. T indicates colon tumor tissues and N represents normal mucosa tissues adjacent to tumor. Quality of total RNA used for RT was evaluated by gel
electrophoresis on 1% denaturing agarose gel and the amount of RT products was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (B)
Endogenous expressionofNDRG2in coloncancercelllineswasalso examinedbyRT–PCR.(C) Expression level ofNDRG2proteinin coloncancercell lineswas
analyzed by western blot analysis. a-Tubulin was used as a loading control. (D) NDRG2 was immunoprecipitated with an anti-NDRG2 antibody, and the
precipitant was analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western Blot analysis using anti-b-catenin antibody. (E) Intracellular
localization of NDRG2 was determined using a confocal microscope. For nuclear staining, 4#,6-diamidino-2-phenylindole (DAPI) was used. NDGR2 introduced
SW620 (SW620/N), HCT116 and Colo205 showed high expression levels of the protein, which localized mainly in the plasma membrane and cytosol.
Inhibition of TCF/b-catenin signaling by NDRG2
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16 h. Cells were then harvested and further cultured for experiments
Plasmids construction and transfection
Full-lengthcomplementaryDNA(cDNA)forhumanNDRG2(NM_201536)was
obtainedfromacDNAlibraryviapolymerasechainreaction(PCR)ampliﬁcation
andcloned intothe BamHI/XhoIsite ofpcDNA3.1(þ) (Invitrogen).Aminoacid
substitution or deletion of human NDRG2 was introduced into the constructed
pcDNA3.1-NDRG2 plasmid using QuikChangeTM Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA) following the instruction manual. The PCR mix-
ture contained 20 ng of template plasmid DNA, 125 ng of each mutagenic
primer, 5 llo f1 0   reaction buffer, 1 ll of dNTPs and 2.5 U PfuTurbo
DNA polymerase (Stratagene) in a total volume of 50 ll. PCR was performed
under the following conditions: denaturation at 95C for 2 min; followed by 16
cycles of denaturation at 95C for 40 s; annealing at 58C for 50 s and extension
at 68C for 15 min. An aliquot of the PCR mixture was analyzed by agarose gel
electrophoresis and was used to transform DH5a competent cells after treatment
with 10 U of DpnI restriction enzyme (Roche, Indianapolis, IN) at 37Cf o r2h .
The integrity of the mutant NDRG2 sequences was conﬁrmed by DNA sequenc-
ing. Cells at 80% conﬂuence were transfected with Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s instructions. The amount of DNA
used for transfection was 1.5 lg per well in a 6-well plate. After 1–4 days, the
transfected cells were washed and harvested for downstream experiments. The
nucleotide sequences for the site-directed mutagenesis are as follows:
NDRG2D302—5#-GCAAGGCATGGGCTAAATGGCCTCATCCTGC-3#,5 #-GC-
AGGATGAGGCCATTTAGCCCATGCCTTGC-3# and NDRG2T334A—5#-CGG-
TCCCGCTCTCGCGCCCTGTCCCAGAGCA-3#,5 #-TGCTCTGGGACAGG-
GCGCGAGAGCGGGACCG-3#.
Luciferase reporter assay
The cells were transfected with TOPﬂash (or FOPﬂash, which harbors mutant
TCF-binding sites) luciferase reporter plasmid (Upstate Biotechnology, Lake
Placid, NY) and the appropriate protein-expressing vectors. b-Galactosidase
was used to normalize the transfection efﬁciency of the cells. Following trans-
fection, 20 mM of LiCl (Sigma) was added to the cells for 6–12 h. After 2 days,
the cells were lysed with lysing buffer (20 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Triton X-100) on ice for 30 min, and the cleared lysates were then
transferred to a 96-well plate, followed by the addition of luciferase assay
reagent (Promega, Madison, WI). The light intensity of the reaction was de-
termined using a plate-reading luminometer (Turner Designs, Sunnyvale, CA)
and luciferase intensity was calculated relative to b-galactosidase activity. All
experimental and control groups contained at least three wells, and the results
were reported as mean absorption ± standard error.
Confocal microscopy
Cells were cultured on coverslips, rinsed three times in cold PBS, ﬁxed with
4% paraformaldehyde at room temperature for 20 min and permeabilized with
0.1% Triton X-100 in PBS for 10 min. Next, the cells were blocked with 1%
bovine serum albumin in PBS for 30 min and then stained with anti-b-catenin
and/or anti-NDRG2 mAbs for 2 h. Finally, the cells were incubated with Alexa
Fluor 488 or 594-conjugated rabbit anti-mouse IgG (Molecular Probe, Eugene,
OR) in dark for 1 h and the nuclei were stained with 4#,6-diamidino-2-phenyl-
indole. The coverslips containing the cells were mounted on glass slides using
VectaShield mounting medium (Vector Laboratories, Burlingame, CA) and
visualized using a Zeiss confocal microscope LSM510META (Carl Zeiss,
Jena, Germany) at  40 magniﬁcation. The confocal images were captured
using the Zeiss LSM Image Browser program.
RT–PCR analysis
Several groups of tissue pairs including normal and cancerous region from pa-
tients with colon cancer were obtained from the tumor tissue bank at Eulji Uni-
versity hospital. Prepared colon cancer tissues were lysed and total RNA was
extracted using TRIZOL reagent (Invitrogen) according to manufacturer’s in-
structions. Five microgram of total RNA was used for reverse transcription to
generate cDNAs using a ProSTAR ﬁrst-strand reverse transcription–polymerase
chainreaction(RT–PCR) kit(Stratagene).PCRreactionfor eachtarget genewas
executedusingthecDNAastemplatewithspeciﬁcprimerpairs.b-Actinwasused
as a reaction standard. The primer pairs that were used are as follows:
NDRG2—5#-GGACATCTTTTCAGCCAGGA-3# (F), 5#- CCCATGCCTTG-
CAGGAAGT-3# (R); b-actin—5#-AGCCGTGGCCATCTCTTGCTCGAAG-3#
Fig. 2. NDRG2 expression in patients with colon carcinoma. NDRG2 was highly expressed in the normal colonic mucosa, but its expression was decreased in
colon cancer tissues as shown by immunohistochemical staining with anti-NDRG2 antibody. (A) Mucosal epithelial cells exhibited strong immunoreaction with
a progressive increase along the crypt toward the upper part from the deeper part ( 40 magniﬁcation). (B) In well-differentiated adenocarcinoma, NDRG2 was
strongly expressed primarily on the cytosolic membrane of tumor cells ( 40 magniﬁcation). The variations of staining in neoplastic cells correlated with the
differentiation state of the tumor. (C) The staining signals in moderately differentiated adenocarcinomatous tissue (arrowhead) were very weak or null ( 20
original magniﬁcation). (D) In poorly differentiated adenocarcinoma (arrowhead), tumor cells did not show any staining, whereas the adjacent normal epithelium
showed strong signals ( 20 original magniﬁcation).
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600(F), 5#-GCCATGTACGTTGCTATCCAGGCTG-3# (R); GAPDH—5#-CCAT-
CACCATCTTCCAGGAG-3# (F), 5#-ACAGTCTTCTGGGTGGCAGT-3# (R);
Cyclin D1—5#-AACTACCTGGACCGCTTCCT-3# (F), 5#-CCACTTGAGC-
TTGTTCACCA-3#(R) and Fibronectin—5#-CGGGAATCTTCTCTGTCAGC-
3# (F), 5#-GCCATGACAATGGTGTGAAC-3#.
Specimen preparation and immunohistochemistry
Tissue specimens obtained from therapeutic procedures were ﬁxed in neutral-
buffered formalin (10% vol/vol formalin in water; pH 7.4) and embedded in
parafﬁn wax. Serial sections of 4 lm thickness were cut and mounted on glass
slides(SuperfrostPlus;FisherScientiﬁc,Rochester,NY).Immunohistochemistry
conditions for NDRG2 were optimized and evaluated by two independent path-
ologists (J.H.K. and H.J.S.). In brief, tissue sections were microwaved twice for
10 min in citrate buffer (pH 6.0) for antigen retrieval. The sections were then
treated with 3% hydrogen peroxide in methanol to quench the endogenous per-
oxidase activity followed by incubation with 1% bovine serum albumin to block
non-speciﬁc binding. Mouse mAb against NDRG2 (clone# 18c12) was used at
a dilution of 1:200 in PBS. The avidin–biotin detection method was used and
tissue sections were immersed in 3-amino-9-ethyl carbazole as a substrate and
thencounterstainedwith10%Mayer’shematoxylin,dehydratedandmountedby
crystal mount. An unrelated mouse IgG was used as a negative control.
Assessment of immunostaining and statistical analysis
Each slide was evaluated for NDRG2 immunoreactivity using a semiquantita-
tive scoring system for both the intensity of the stain and the percentage of
positive neoplastic cells. NDRG2 immunoreactivity was observed primarily in
the cytosolic membrane, although cytosolic expression of NDRG2 was noted
in some colorectal mucosal and malignant cells. The intensity of membrane or
cytosolic staining was scored using the following system: 0, lower than the
adjacent normal-appearing mucosal epithelium; 1, similar to the adjacent mu-
cosal epithelium; 2, stronger than the adjacent mucosal epithelium. The per-
centage of cells displaying a stronger staining intensity than the adjacent
mucosal epithelium was scored as 1 (0–24% tumor cells stained); 2 (25–
49% tumor cells stained); 3 (50–74% tumor cells stained); 4 (75–100% tumor
cells stained). For the purpose of statistical analysis, the median of this series
(25% of malignant cells showing a stronger intensity than adjacent mucosal
epithelium) was used as a cutoff value to distinguish tumors with a low
(,25%) or high ( 25%) level of NDRG2 expression. The relationship be-
tween the results of the immunohistochemical study and the clinicopathologic
parameters was determined using the SAS software package (version 9.01;
SAS Institute, Cary, NC). The correlation between staining index scores and
other categorical factors was analyzed using the Pearson’s chi-square test of
independence. Results were considered statistically signiﬁcant at P , 0.05.
Results
NDRG2 mRNA was expressed differentially in human colon
carcinoma tissues and colon cancer cell lines
To compare NDRG2 expression levels in colon cancer tissues, we
examined the messenger RNA (mRNA) level of NDRG2 by perform-
ing RT–PCR analysis on pairs of tissue containing normal and tumor
tissues from the same donor. b-Actin was used as a reference gene to
correct for the variations in the amount of mRNA in individual sam-
ples. As shown in Figure 1A, 20 cases of colon cancer tissues ran-
domly selected from clinically diagnosed patients showed signiﬁcant
decrease of NDRG2 mRNA expression compared with normal tissue
from the same patients. RT–PCR analyses also showed differential
expression of NDRG2 in human colon cancer cell lines, which was
especially high in HCT116 and Colo205 cell lines (Figure 1B). The
levels of NDRG2 mRNA in colon cancer cell lines correlated with
those of NDRG2 protein as shown by western blot analysis (Figure
1C). SW620 cell was shown very slightly expressed NDRG2 protein.
NDRG2 was localized mainly on plasma membrane and cytosol of
colon cell lines
Analysis using confocal microscopy gave evidence that the endoge-
nous form of the intracellular NDRG2 protein was also recognized by
the generated mAb. Western blot analysis in colon cancer cell lines
showed that intracellular NDRG2 was localized mainly in the plasma
membrane of the colon cancer cells, HCT116 and Colo205, which
exhibited high expression level of NDRG2 protein (Figure 1C and E).
Additionally, the exogenously introduced NDRG2 was localized
mainly in the plasma membrane and cytosol of the SW620 colon
cancer cell line, although a small proportion of the NDRG2 was also
observed in the nucleus (Figures 1E and 3C).
NDRG2 expression in diverse colon cancer tissues
Expression levels and patterns of NDRG2 in human colorectal carci-
nomas were evaluated by immunohistochemical analysis (Figure 2).
NDRG2 was highly expressedin normal colonic mucosa (100%) from
patients both in the cytosol and plasma membrane (Figure 2A). In
addition, staining was well preserved in the dysplastic epithelial cells
in all adenomatous polyps that were examined. A high level of
NDRG2 expression was observed in 44 (44%) of 99 patient’s tissues
with colorectal cancer. NDRG2 was distributed primarily in the
cytosolic membrane and partly in the cytosol of tumor cells. The
variations of staining intensity were dependent on tumor differentia-
tion. NDRG2 was distinctively expressed in well-differentiated co-
lorectal carcinomas (Figure 2B) compared with moderately and
Table II. Multivariate logistic regression analysis with the expression status
of NDRG2
Categories Odds ratio 95% Conﬁdence
limits
P-value
Differentiation ,0.0001
Moderately versus well 0.150 0.047–0.477
Poorly versus well 0.017 0.002–0.200
Dukes’ stage 0.002
Dukes A versus C 10.195 2.092–49.69
Dukes B versus C 0.698 0.210–2.314
Table I. Clinicopathologic parameters and the expression status of NDRG2
Characterstics Total NDRG2 expression level P
Negative/low High
n % n %
Age (years) 0.0561
,50 37 27 73.0 10 27.0
 50 62 28 45.2 34 54.8
Gender 0.1795
Female 51 25 49.0 26 51.0
Male 48 30 62.5 18 37.5
Site 0.5187
Right/transverse colon 28 17 60.7 11 39.3
Left colon and rectum 71 38 53.5 33 46.5
Size 0.4251
,5 cm in diameter 60 32 53.3 28 46.7
 5 cm in diameter 39 23 59.0 16 41.0
Differentiation ,0.0001
Well 28 5 17.9 23 82.1
Moderately 46 25 54.3 21 45.7
Poorly 25 25 100 0 0
Invasion depth 0.0015
T1 3 0 0 3 100
T2 18 4 22.2 14 77.8
T3 72 48 66.7 24 33.3
T4 6 3 50.0 3 50.0
Nodal status 0.0719
N0 44 20 45.5 24 54.5
N1 55 35 63.6 20 36.4
Distant metastasis 1.00
M0 90 50 55.6 40 44.4
M1 9 5 55.6 4 44.4
Dukes’ stage 0.0004
A 17 2 11.8 15 88.2
B 27 18 66.7 9 33.3
C 55 35 63.6 20 36.4
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601poorly differentiated tumor tissues (Figure 2C and D) in all of the
cases examined. In some moderately or poorly differentiated cases,
staining was heterogenous with faint labeling alternating with areas
displaying no labeling. Interestingly, NDRG2 was more strongly
expressed in the well-differentiated area than the less-differentiated
area even in the same colon tissue of each patient. NDRG2 was ex-
pressed in colon cancer tissues in a tumor invasion depth-dependent
manner; NDRG2 expression was signiﬁcantly lower in advanced co-
lorectal carcinomas compared with normal mucosal tissues or early
invasive cancer tissues from the same cancer patients. Notably, nor-
mal dendritic cells exhibited cytologic labeling for NDRG2 in the
tumor areas.
Association of NDRG2 expression levels and clinicopathological
characteristics in colorectal cancer
We ﬁrst examined whether the expression level of NDRG2 correlated
with clinicopathological prognostic parameters. The analysis showed
that the expression level of NDRG2 positively correlated with histo-
logic tumor differentiation but inversely correlated with tumor inva-
sion depth and clinical Dukes’ stage in univariate analysis (Table I).
We carried out multivariate logistic analyses to assess the predictive
value of NDRG2 expression status for clinicopathologic signiﬁcance
by adjusting other potentially prognostic parameters. The results cor-
roborated that tumor differentiation and the expression level of
NDRG2 was a signiﬁcant covariate; however, clinical Dukes’ stage
and high level of NDRG2 expression was a reverse covariate, respec-
tively (Table II). A possible inverse correlation between high NDRG2
expression and tumor size (P 5 0.054) or the presence of nodal me-
tastasis (P 5 0.0719) was notable, although the values did not reach
statistical signiﬁcance at the level of 0.05. These ﬁndings suggest the
possibility that NDRG2 protein might play a role in the maintenance
of differentiation of colorectal epithelial cells and the delay of de-
velopment and progression of human colorectal adenocarcinoma.
TCF/b-catenin signaling was reduced in NDRG2 overexpressing cells
ToelucidatetheeffectofNDRG2onthedifferentiationofcoloncancer
cells, reporter assays for several transcription factor activities were
developed via transient transfection in SW620 and KM12c colon can-
cer cell lines. Introductionoffull-length NDRG2 induced the decrease
of TCF/LEF transcription activity in HCT116 and SW620 cell lines
(Figure 3A), whereas the activities of activator protein-1 (AP-1) were
slightly reduced in both cell lines (Figure 3A). The reduced activity of
AP-1 induced growth retardation (27) and colonocyte differentiation
(25). To further study the regulation of TCF/b-catenin signaling by
NDRG2,weestablishedSW620celllinesthatexpressNDRG2protein
constitutively (SW620/N). Interestingly, b-catenin expression was de-
creased in all of the four selected cell clones (Figure 3B), although
there was no signiﬁcant change in its localization induced by NDRG2
introduction (Figure 3C). Immunoprecipitation with anti-NDRG2 an-
tibody was carried out to verify interacting of NDRG2 with b-catenin.
b-Catenin was detected in the precipitate (Figure 1D). Western blot
analysis of colon cancer cell lines showed that NDRG2 was separated
into two bands (Figure 1C). We hypothesized that the slow migrating
band is a phosphorylated form of the faster migrating band because
the slow migrating band disappeared when the threonine residue at
334 amino acid (which matches with the 348th amino acid in the
longer form of NDRG2, NDRG2a) was changed into alanine by
site-directed mutagenesis. NDRG2T334A protein exhibited the same
migration rate as the higher migrating band of wild-type NDRG2 and
could not induce the decrease of b-catenin expression. The level of b-
catenin protein was not changed by the overexpression of NDRG2D302
nor by the overexpression of NDRG2T334A (Figure 3D).
Fig. 3. ModulationofTCF/b-cateninsignalingby NDRG2. TOPﬂashluciferasereporterassaysystemcontaininga luciferasereporterplasmidwiththreecopiesof
the optimal TCF-/LEF-binding sites upstream of the minimal thymidine kinase promoter was used to elucidate the role of NDRG2 in modulation of Wnt/b-catenin
signaling. (A) Transiently transfected NDRG2 induced the decrease of TCF/LEF transcription activity in SW620 and HCT116. NDRG2 was overexpressed in
SW620 cells, which originally expressed low levels of NDRG2. (B and C) Signiﬁcant reduction in b-catenin expression was observed in the four selected clones,
but its localization was not changed. (D) Mutant forms of NDRG2, NDRG2T334A and NDRG2D302 generated by site-directed mutagenesis did not induce
downregulation of b-catenin. M and T represent cells transfected with empty vector or NDRG2-expressing vector, respectively.
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Protein stability of b-catenin is known to be regulated by the kinase
activity of GSK-3b that seemed to be affected by NDRG2 function.
TCF/LEF activity in SW620 cells was enhanced by treatment with
LiCl, a well-known GSK-3b inhibitor, as well as by cotransfection of
b-catenin. NDRG2-induced decrease of TCF/LEF activity was also
detected under these enhanced conditions (Figure 4A). The data that
NDRG2 attenuated the increase of TCF/LEF activity following LiCl
treatment support the notion that NDRG2 may regulate the kinase
activity of GSK-3b. Mutants NDRG2, NDRG2T334A, NDRG2T334D
and NDRG2D302 showed no effect on the transcription activity of
TCF/LEF (Figure 4B). Otherwise, as the expression of NDRG2 was
downregulated by NDRG2 siRNA, the protein level of b-catenin was
increased (Figure 4C). As shown in Figure 4D, the inhibitory phos-
phorylation of GSK-3b at Ser9 and Akt was reduced in SW620-
NDRG2 cell line, which activated the kinase activity of GSK-3b
and induced the degradation of b-catenin protein. The effect of
NDRG2 on TCF/b-catenin signaling was veriﬁed by RT–PCR analy-
sis of TCF/LEF target genes. Cyclin D1 and ﬁbronectin are known to
have TCF-/LEF-binding sites in their promoter regions and their tran-
scription was decreased by NDRG2 expression (Figure 4E). However,
their expression was not changed in SW620-NDRG2T334A and
SW620-NDRG2D302, indicating that NDRG2 phosphorylation in its
C-terminal region is critical to the regulation of the TCF/LEF tran-
scription activity. As expected, NDRG2T334A and NDRG2D302
showed no effect on the phosphorylation status of GSK-3b or on
the degradation of b-catenin (Figures 3D and 4D).
Discussion
NDRG2 has been studied in a number of cell and animal systems, and
it has been shown to inﬂuence diverse cellular processes such as
differentiation and proliferation, although its exact molecular mech-
anism is not yet known. In this study, we discovered that NDRG2
expression decreases with tumor stages and modulates the transcrip-
tional activity of TCF/LEF through the regulation of b-catenin stabil-
ity, which relates NDRG2 function with tumorigenesis of colon cells.
The TCF/b-catenin-signaling pathway has been implicated in the reg-
ulation of colonic epithelial cell proliferation and differentiation (19–
21). For the ﬁrst time, we showed that the upregulation of NDRG2
induced the downregulation TCF/b-catenin signaling in human colon
cancer cells.
The intracellular concentration of b-catenin is regulated by its deg-
radation, which occurs via interaction with APC tumor suppressor
protein and phosphorylation at its N-terminus through the interaction
Fig. 4. NDRG2 regulates the phosphorylation of GSK-3b.( A) NDRG2 introduction attenuated the increase of TCF/LEF activity following LiCl or b-catenin
treatment. (B) Mutant NDRG2, NDRG2T334A and NDRG2D302 showed no effect on the transcription activity of TCF/LEF. (C) SW620/N was treated with NDRG2
siRNA. The reduction of NDRG2 mRNA and protein levels by siRNAwas conﬁrmed by RT–PCR and western blot analyses. The protein level of b-catenin was
increased in the NDRG2 siRNA-introduced cells. (D) The suppression of LiCl-induced TCF activation by NDRG2 presented the possible function of NDRG2 in
the regulation of GSK-3b activity, and the inhibitory phosphorylation of GSK-3b was reduced by NDRG2 overexpression. (E) Target genes of TCF/LEF
transcription factor were downregulated following NDRG2 introduction.
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603with GSK-3b (28–31). In the majority of sporadic colorectal cancer
cases, the rate-limiting event is either loss of APC function or onco-
genic b-catenin mutations, which makes b-catenin resistant to pro-
teolytic degradation. Intracellular b-catenin accumulation eventually
results in the formation of b-catenin–TCF complex and its nuclear
translocation, followed by the stimulation of tumor formation via
increases in the expression of c-Myc and cyclin D1 (32,33). Our data
show that NDRG2 introduction into SW620 cells induces a decrease
in GSK-3b phosphorylation, which increases its kinase activity
(Figure 4D) and subsequently induces b-catenin downregulation (Fig-
ures 3D and 4C). SW620 cell line is known to have a mutant APC type
and wild-type b-catenin. Large proportion of b-catenin in wild-type
SW620 cell linewas shown to localize in the nucleus (Figure 3C). The
decrease of intracellular b-catenin following the introduction of
NDRG2 in this cell type induces the decrease of nuclear b-catenin,
which then results in the attenuation of TCF/LEF activity.
We also showed that the phosphorylation of NDRG2 might be
essential for the regulation of TCF/b-catenin signaling. The data from
NDRG2 mutants showed that the phosphorylation of NDRG2 is crucial
for activating TCF/LEF signaling. The mutant forms of NDRG2,
including NDRG2D302,N D R G 2 T334A and NDRG2T334D, showed no
effect on the transcription activity of TCF/LEF (Figure 4B). Addition-
ally, the expression levels of ﬁbronectin and cyclin D1, which are well
known as being modulated by TCF/LEF transcriptional activity, were
reduced only in wild-type NDRG2-overexpressing cells (Figure 4E).
Threonine residue at the 334 amino acid position is known to be phos-
phorylated by Akt kinase. Further, examination of the (phosphoinosi-
tide 3-kinase/Akt) pathway in relation to NDRG2 function in TCF/b-
catenin signaling is needed to elucidate its roles in tumor development.
The mAb that was generated with speciﬁc binding capability was
used to determine NDRG2 expression in human colon cancer tissues.
The data from immunohistochemical analysis are noteworthy in that
NDRG2 is expressed in the well-differentiated tumor tissues and the
earliest stage of colon cancer, but the more advanced and poorly
differentiated tumor tissues showed lower or no NDRG2 expression
levels (Figure 2, Table I). Normal colonic mucosa and premalignant
lesions such as dysplasia showed well-deﬁned membraneous expres-
sion of NDRG2 in colon cells (Figure 2). Recently, Lorentzen et al.
(34) reported that NDRG2 expression was downregulated at a late
stage in colorectal carcinogenesis. The biological role of NDRG2 as
suppressor of metastasis was reported in liver cancer (35). Guan et al.
(36) reported that DRG1 expressed primary colonic and metastatic
tumors as well as eight cancer cell lines (including SW620 and Co-
lo205 cells) and it might be an element in colonic epithelial cell
differentiation because its expression was downregulated in meta-
static lesions and cell lines, and overexpression induced differentia-
tion and suppressed invasiveness like as those of NDRG2. Our data
correlate with their RT–PCR data and present the same question,
whether NDRG2 downregulation is a cause or a consequence of tumor
cell malignancy.
The TCF/b-catenin inhibitory activities of NDRG2 suggest that
colon cancer with higher NDRG2 levels is probably to correspond
with better biologic behavior and clinical prognosis (Figure 2, Tables I
and II). Considering the potential modulator of additional therapies,
the TCF/b-catenin inhibitory activities of NDRG2 would also be
important in providing a novel strategy for the treatment of cancer
and its metastasis.
The role of Akt/GSK-3b/b-catenin transduction pathway has been
investigated in muscle anti-atrophy action (37), in adipogenesis (38)
and in cell cycle progression (39). Schakman et al. (37) reported that
muscle atropy induced by dexamethasone administration occurred
with decrease in Akt phosphorylation together with a decrease in
b-cateninproteinlevels.Here,wesuggestthatNDRG2mightbecrucial
for TCF/b-catenin signaling and that this TCF/b-catenin signal regu-
lation is mediated through the phosphorylation of NDRG2 as well as
the phosphorylation of GSK-3b. However, the regulatory mechanism
of NDRG2 phosphorylation and its role in the control of GSK-3b
activity should be examined more deeply. Thus, further studies will
be required in order to clarify and elucidate the mechanisms under-
lying NDRG2-mediated inhibition of TCF/b-catenin signaling in the
tumorigenesis of human colorectal cancer.
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